Have you found yourself asking, "Why are my Medicaid rebates so high?" You're not alone. Many of our clients pose this very question. To help you understand and manage your Medicaid rebate liability, we examine three critical areas. This white paper will guide you...
Navigating the Changing Landscape of Pharmaceutical State Price Transparency Reporting In the world of pharmaceutical manufacturing, staying up to date on regulatory changes and market dynamics is essential for success. Recently, there has been a significant shift...
MASTERING BEST PRACTICES: Vetting Previously Marketed Pharmaceutical Drug AcquisitionsPharmaceutical manufacturers considering the acquisition of pre-existing drugs face the challenge of conducting a meticulous and comprehensive analysis across a spectrum of...
2024 AMP CAP REMOVAL What You Need To Know2024 AMP CAP REMOVAL – WHAT PHARMA MANUFACTURERS NEED TO KNOWThe 2024 Medicaid AMP cap removal will be effective January 1st, 2024, and may have sweeping impacts for drug manufacturers participating in the Medicaid program....
2023 DRUG WASTAGE RULE TO IMPACTPHARMA MANUFACTURERSPharmaceutical manufacturers continue to experience regulatory and program changes that result in new rebates and/or penalties which have the potential to negatively impact profitability. Last year, the Inflation...
Chargeback Processing — Best Practices to Avoid Revenue Leakage & RiskChargeback processing, validation, and reconciliation are integral in maintaining a profitable business in the highly competitive U.S. pharmaceutical market. Profit margins are tight, especially...
MEDICAID REBATE LIABILITY FORECASTING AFTER UNWINDING, PUERTO RICO INCLUSIONFor pharmaceutical manufacturers accruing for Medicaid rebate liabilities, new updates on continuous enrollment unwinding from the COVID Public Health Emergency and the addition of Puerto Rico...
Update – Inflation Reduction Act Rebate Provisions for Pharma ManufacturersInflation Reduction Act – new updates! On August 16th, 2022, the Inflation Reduction Act (IRA) of 2022 was signed into law, creating potential impacts for drug manufacturers in the way of...
CMS Enforcement of Average Sales Price (ASP) Submissions for all Medicare Part B Eligible Pharmaceuticals and BiopharmaceuticalsRecently, CMS has been sending letters to pharma and biopharma manufacturers (with and without MDRP agreements) indicating that they believe...